mani
virus
use
program
ribosom
frameshift
increas
code
capac
genom
regul
stoichiometr
ratio
viral
protein
two
gene
gag
pol
encod
viral
structur
protein
enzym
respect
overlap
nt
synthesi
gagpol
polyprotein
requir
ribosom
frameshift
ratio
gag
gagpol
crucial
viru
propag
dysregul
detriment
replic
virion
format
infect
effici
gagpol
human
cell
rang
differ
report
effici
recapitul
vivo
vitro
mammalian
yeast
escherichia
coli
translat
extract
suggest
viru
exploit
evolutionari
conserv
featur
translat
apparatu
govern
two
cisact
element
mrna
slipperi
site
encod
phe
uuu
leu
uua
stemloop
sl
structur
downstream
slipperi
site
figur
give
rise
two
frameshift
product
one
contain
peptid
pheleu
follow
sequenc
flr
product
figur
b
anoth
second
phe
incorpor
instead
leu
ffr
product
mammalian
cell
frameshift
ribosom
insert
leu
like
insert
phe
posit
also
e
coli
product
produc
flr
constitut
product
hiv
frameshift
product
heterogen
may
result
frameshift
addit
gagpol
gene
second
put
slipperi
site
nt
downstream
canon
slipperi
site
also
conserv
albeit
lesser
degre
first
slipperi
site
sequenc
particularli
slipperi
substitut
u
appear
compensatori
resist
mutat
antihiv
therapi
may
facilit
addit
fs
otherwis
silent
site
mechan
frameshift
gagpol
mrna
factor
defin
ratio
two
product
unclear
varieti
propos
mechan
uncertain
signific
second
slipperi
site
lack
mechanist
inform
altern
slippag
eg
prompt
us
studi
gagpol
frameshift
real
time
fulli
reconstitut
vitro
translat
system
show
fs
pathway
effici
determin
avail
leutrnaleu
read
uua
codon
potenti
altern
slippag
also
oper
aminoacyltrna
aatrna
limit
suppli
show
uuaspecif
trnaleu
particularli
rare
human
cell
line
deriv
tlymphocyt
cell
target
furthermor
character
role
second
slipperi
site
support
multipl
way
modul
frameshift
effici
could
help
viru
maintain
gag
gagpol
ratio
crucial
viabil
experi
prokaryot
translat
compon
includ
kinet
measur
summar
supplementari
tabl
carri
hifi
buffer
mm
ph
mm
mm
kcl
mm
mm
putrescin
mm
spermidin
mm
dtt
state
otherwis
ribosom
e
coli
initi
factor
elong
factor
eftu
efg
fmettrnafmet
bodipymettrnafmet
phetrnaph
prepar
e
coli
describ
gln
ala
asntrna
mixtur
argtrnaarg
glytrnagli
valtrnav
prepar
e
coli
total
trna
aminoacyl
respect
amino
acid
subsequ
affin
chromatographi
ternari
complex
protino
niida
pack
column
machereynagel
follow
phenol
ethanol
precipit
aatrna
trnanaaleu
elong
trnamet
trnatyr
mixtur
isoacceptor
trnaleu
collect
read
four
cun
codon
leu
prepar
consecut
column
chromatographi
sepharos
ge
healthcar
phenyl
sepharos
ge
healthcar
deae
toyopearl
tosoh
bioscienc
trnatrp
prepar
rnapolymeras
transcript
plasmid
carri
e
coli
trp
gene
trna
charg
unlabel
amino
acid
leutrnanaaleu
mixtur
isoacceptor
leutrna
cun
codon
mettrnaemet
iletrnail
tyrtrnatyr
purifi
reversedphas
hplc
column
mm
mm
merck
equilibr
mm
ammonium
acet
ph
mm
magnesium
acet
mm
nacl
use
gradient
ethanol
concentr
determin
spectrophotometr
nm
scintil
count
applic
ultima
gold
xr
perkin
elmer
total
human
aatrna
prepar
hela
cell
extract
cytoplasm
fraction
cell
lysat
phenol
aatrna
purifi
anionexchang
chromatographi
hitrap
q
hp
column
ml
ge
healthcar
equilibr
mm
sodium
acet
ph
mm
use
gradient
kcl
use
nativ
sequenc
gagpol
frameshift
motif
nt
complet
genom
ncbi
refer
sequenc
clone
vector
mutat
introduc
sitedirect
mutagenesi
use
dnapolymeras
neb
supplementari
tabl
mrna
prepar
vitro
transcript
rnapolymeras
purifi
use
rneasi
maxi
kit
qiagen
accord
manufactur
recommend
control
mrna
use
determin
rate
argtrnaarg
incorpor
supplementari
figur
made
chemic
synthesi
iba
contain
e
coli
shinedalgarno
sd
sequenc
insert
nt
upstream
start
codon
aug
translat
bacteri
translat
system
sd
sequenc
insert
hiv
mrna
nt
upstream
start
codon
aug
short
mrna
use
codon
walk
experi
aug
introduc
nt
upstream
length
sequenc
follow
nt
encompass
mrna
use
studi
frameshift
ggg
codon
gli
follow
slipperi
site
mutat
ugg
trp
distinguish
product
nearest
natur
aug
gag
mrna
use
start
codon
long
mrna
studi
gagpol
translat
product
page
stop
codon
uag
introduc
nt
downstream
aug
nt
allow
separ
aa
aa
product
control
mrna
contain
respect
sequenc
clone
infram
mutat
prevent
slippag
mrna
contain
nt
harbor
hiv
mrna
eukaryot
translat
contain
nativ
utr
rabbit
mrna
kozak
sequenc
embed
augg
site
allow
effici
initi
start
codon
aug
place
nt
upstream
slipperi
site
next
codon
cag
gln
mutat
gag
val
improv
initi
facilit
product
separ
hplc
eukaryot
mrna
contain
nt
downstream
cover
mrna
sequenc
list
supplementari
tabl
aug
bold
slipperi
site
underlin
uag
stop
codon
ital
mutat
nucleotid
small
letter
bold
initi
complex
ic
prepar
incub
ribosom
mrna
initi
factor
initi
f
mettrnafmet
bodipymettrnafmet
dtt
mm
gtp
mm
hifi
buffer
min
ic
use
codonwalk
experi
purifi
ultracentrifug
sucros
cushion
buffer
mm
trishcl
ph
mm
mm
kcl
mm
dissolv
hifi
buffer
form
ternari
complex
tc
eftu
excess
aatrna
incub
gtp
mm
phosphoenolpyruv
mm
pyruv
kinas
mgml
buffer
dtt
mm
min
aatrna
ad
incub
min
concentr
aatrna
optim
ensur
maximum
bind
respect
codon
glntrnagln
alatrnaala
asntrnaasn
phetrnaph
argtrnaarg
glytrnagli
differ
concentr
leutrnanaaleu
indic
ic
mix
tc
final
concentr
eftu
efg
gtp
mm
phosphoenolpyruv
mm
pyruv
kinas
mgml
hifi
buffer
incub
time
min
time
cours
min
endpoint
measur
stabil
peptidyltrna
bind
ribosom
test
nitrocellulos
filter
bind
assay
supplementari
figur
prepar
sampl
hplc
analysi
reaction
quench
koh
hydrolyz
min
sampl
neutral
addit
acet
acid
translat
product
separ
reversedphas
hplc
column
merck
appli
adapt
gradient
acetonitril
trifluoroacet
acid
elut
fraction
mix
ultima
gold
xr
scintil
liquid
perkin
elmer
analyz
scintil
count
peptid
product
mqan
separ
peptid
could
identifi
either
posit
shift
chromatogram
radioact
label
respect
amino
acid
amount
product
determin
ratio
respect
peak
total
eluat
sampl
glytrnagli
argtrnaarg
leu
trnanaaleu
respect
peak
calcul
pmol
necessari
amount
mqanflr
peptid
calcul
subtract
mqanflg
mqanfl
pmol
likewis
mqanffr
peptid
calcul
subtract
mqanflr
mqanflrffr
mixtur
product
pmol
time
cours
evalu
numer
integr
kintek
explor
softwar
frameshift
effici
calcul
ratio
peptid
mqanffr
mqanflr
sum
peptid
mqanf
mqanfl
mqanflg
multipli
translat
mrna
carri
describ
codonwalk
assay
glntrnagln
alatrnaala
asntrnaasn
phetrnaph
leutrnanaaleu
trptrnatrp
mettrnaemet
tyrtrnatyr
ic
mix
tc
final
concentr
eftu
efg
gtp
mm
phosphoenolpyruv
mm
pyruv
kinas
mgml
hifi
buffer
effici
frameshift
peptid
synthesi
calcul
divid
amount
respect
peptid
pmol
sum
peptid
translat
exclud
mqan
multipli
form
posttransloc
complex
purifi
ic
final
mix
phetrnaph
leu
trnanaaleu
presenc
efg
ic
concentr
hifi
buffer
incub
min
posttransloc
complex
mix
argtrnaarg
efg
react
posit
mfr
mlr
peptid
identifi
base
arg
count
amount
calcul
pmol
rate
arg
incorpor
estim
exponenti
fit
graphpad
prism
softwar
ic
prepar
bodipymettrnafmet
incub
eftu
total
aatrna
hela
cell
efg
gtp
mm
phosphoenolpyruv
mm
pyruv
kinas
mgml
hifi
buffer
indic
time
cours
translat
min
singlepoint
measur
case
translat
carri
use
ic
eftu
total
aatrna
hela
efg
gtp
mm
phosphoenolpyruv
mm
pyruv
kinas
mgml
min
hifi
buffer
prepar
sampl
page
reaction
stop
naoh
hydrolyz
describ
hplc
sampl
prepar
hepe
ph
ad
neutral
reaction
sampl
separ
tristricin
gel
electrophoresi
fluoresc
peptid
visual
use
scanner
ge
healthcar
life
scienc
band
intens
evalu
use
multigaug
softwar
frameshift
effici
calcul
band
intens
product
sum
product
well
translat
intermedi
appear
translat
correct
length
peptid
confirm
use
control
mrna
ribosom
subunit
hela
translat
initi
factor
translat
elong
factor
well
mettrnamet
prepar
accord
publish
protocol
ic
form
incub
subunit
molar
excess
excess
excess
mrna
excess
mettrnamet
mammalian
translat
mt
buffer
mm
ph
mm
kcl
mm
mm
spermidin
mm
atp
mm
gtp
min
form
ic
equal
volum
mt
buffer
contain
subunit
ad
initi
reaction
mix
incub
min
elong
reaction
mix
prepar
incub
elong
trna
mix
total
human
trna
aminoacyl
val
ala
asn
phe
leu
arg
gli
phosphoenol
pyruv
mm
mm
pyruv
kinas
mt
buffer
min
experi
shown
supplementari
figur
leu
arg
use
figur
arg
radioact
label
start
translat
equal
volum
elong
reaction
mix
ad
initi
reaction
mix
incub
min
sampl
prepar
hplc
hplc
analysi
quantif
radioact
peptid
done
describ
bacteri
translat
system
peptid
identifi
base
arg
presenc
leu
total
translat
effici
quantifi
use
leu
frameshift
effici
calcul
ratio
argcontain
peptid
total
translat
product
multipli
absenc
leu
total
translat
effici
calcul
use
control
show
maximum
level
frameshift
peptid
produc
given
condit
frameshift
effici
calcul
ratio
argcontain
wt
peptid
control
peptid
multipli
cell
deriv
nonhodgkin
tcell
lymphoma
isol
pleural
effus
male
subclon
soft
agar
jurkat
cell
deriv
human
tcell
lymphoblast
cell
deriv
human
cutan
tcell
lymphoma
cell
line
deriv
peripher
blood
patient
sezari
syndrom
cell
fusion
product
human
bcell
line
human
tcell
line
cem
epitheli
cell
line
deriv
human
embryon
kidney
cell
express
larg
antigen
inform
cell
line
taken
http
aidsreagentorg
http
wwwlgcstandardsatccorg
dsmzgerman
collect
microorgan
cell
cultur
acc
cell
maintain
dulbecco
modifi
eagl
medium
dmem
pan
biotech
supplement
fetal
calf
serum
biochrom
fc
concentr
penicillinstreptomycin
penstrep
mix
pan
biotech
subcultur
cell
detach
resuspens
phosphatebuff
salin
pb
incub
trypsinedta
solut
pan
biotech
human
tcell
line
nih
aid
reagent
program
nih
aid
reagent
program
jurkat
nih
aid
reagent
program
maintain
roswel
park
memori
institut
medium
rpmi
pan
biotech
supplement
fc
concentr
penstrep
mix
subcultur
cultur
medium
contain
suspens
cell
centrifug
g
min
room
temperatur
supernat
discard
pellet
cell
resuspend
ml
rpmi
medium
ml
suspens
ad
new
cultur
flask
fill
ml
rpmi
medium
cellular
trna
level
trnauaaleu
trnacagleu
trnauacval
trnacacv
quantifi
use
strategi
publish
total
cellular
rna
extract
use
rneasi
mini
kit
qiagen
accord
manufactur
protocol
elut
rna
content
determin
spectrophotometr
elimin
potenti
coisol
dna
sampl
rna
incub
dnase
new
england
biolab
final
volum
min
final
heat
min
inactiv
enzym
primer
revers
transcript
entail
trnaspecif
sequenc
stemloop
sequenc
trnaspecif
primer
trnauaaleu
trnacagleu
complementari
posit
differ
trnacacv
trnauacval
complementari
posit
supplementari
tabl
cdna
synthesi
perform
describ
manufactur
instruct
genespecif
primer
use
superscript
iii
firststrand
synthesi
system
thermofish
scientif
dnase
idigest
rna
input
rna
remov
incub
rnase
h
determin
level
trna
trnauaaleu
trnacagleu
trnauacval
trnacacv
well
rrna
housekeep
gene
control
quantit
pcr
qpcr
perform
employ
quantitect
sybr
green
kit
qiagen
accord
manufactur
protocol
rotorgen
q
devic
qiagen
primer
use
qpcr
taken
forward
primer
qpcr
highli
specif
trna
revers
primer
univers
supplementari
tabl
run
technic
triplic
analyz
sampl
reaction
contain
water
instead
templat
cdna
use
neg
control
cycl
condit
chosen
follow
one
cycl
min
follow
cycl
consist
final
linear
temperatur
increas
ramp
per
step
step
last
perform
obtain
melt
curv
reaction
order
compar
trnauaaleutrnacagleu
rnauacval
trnacacv
trna
ratio
cell
line
cycl
threshold
ct
valu
trna
normal
respect
ct
valu
rrna
first
aim
solv
mechan
mrna
mechanist
work
use
fulli
reconstitut
translat
system
e
coli
overal
effici
ratio
flr
ffr
product
similar
mammalian
cell
e
coli
function
center
ribosom
frameshift
take
place
highli
conserv
eukaryot
prokaryot
feasibl
prepar
materi
reconstitut
eukaryot
translat
system
amount
need
type
analysi
first
test
potenti
rout
frameshift
model
gagpol
mrna
encompass
natur
frameshift
site
translat
start
codon
aug
three
codon
upstream
slipperi
site
figur
form
initi
complex
mrna
fmettrnafmet
start
translat
addit
ternari
complex
elong
factor
ef
desir
combin
purifi
aatrna
consecut
amino
acid
incorpor
result
peptid
fmetglnalaasnpheleugli
mqanflg
peptid
fmetglnalaasnpheleuarg
mqanflr
fmetglnalaasnphephearg
mqanffr
peptid
analyz
reversedphas
hplc
rphplc
supplementari
figur
overal
frameshift
effici
determin
yield
arg
incorpor
rel
sum
peptid
mrna
contain
nativ
slipperi
sequenc
larg
fraction
peptid
contain
arg
figur
indic
effici
expect
mutat
chang
sequenc
u
uuc
uua
abolish
fs
figur
supplementari
figur
principl
occur
decod
step
translat
elong
cycl
peptidyltrna
bound
p
site
ribosom
site
vacant
transloc
two
trna
togeth
mrna
move
ribosom
slippag
occur
decod
effici
must
depend
competit
aatrna
leutrna
phetrna
bind
uuua
sequenc
fact
addit
leutrnanaaleu
e
coli
trna
read
uua
uug
codon
anticodon
indic
subscript
n
posttranscript
modifi
nucleotid
dramat
lower
effici
absenc
presenc
leutrnanaaleu
figur
contrast
mixtur
nearcogn
leutrna
isoacceptor
collect
read
cun
famili
leu
codon
effect
high
effici
observ
absenc
leutrnanaaleu
indic
ribosom
slip
prior
independ
leu
incorpor
estim
ratio
leu
phe
arg
incorpor
product
determin
pathway
chang
leutrnanaaleu
concentr
figur
absenc
leutrnanaaleu
ffr
product
form
upon
addit
leutrnanaaleu
flr
product
becom
preval
thu
frameshift
gagpol
slipperi
site
switch
two
regim
preval
depend
concentr
critic
trna
leu
incorpor
follow
differ
rout
take
place
either
trnaleu
transloc
upon
decod
follow
gli
codon
frameshift
took
place
decod
glytrnagli
argtrnaarg
compet
bind
ribosom
howev
observ
effici
independ
glytrnagli
argtrnaarg
concentr
figur
find
suggest
slippag
commit
new
read
frame
occur
leu
incorpor
prior
decod
next
codon
gli
argtrna
similar
wellstudi
case
ibv
dnax
mrna
slippag
occur
late
stage
transloc
slipperysit
trna
suggest
similar
twotrna
frameshift
mechan
uua
codon
particularli
rare
human
cell
respect
leutrnanaaleu
underrepres
cell
type
see
format
ffr
product
depend
slippag
hungri
uua
codon
test
whether
allow
also
note
normal
slippag
event
would
lead
prematur
termin
due
stop
codon
appear
frame
downstream
frameshift
site
peptid
difficult
detect
vivo
altern
slippag
event
could
chang
ratio
gag
gagpol
polyprotein
distinguish
product
chang
ggg
gli
codon
follow
slipperi
site
ugg
trp
figur
supplementari
figur
mutat
affect
effici
vivo
human
cell
addit
aatrna
need
translat
mqanfl
sequenc
ad
purifi
trptrnatrp
w
elong
mettrnamet
tyrtrnatyr
expect
peptid
mqanflw
peptid
mqanffm
mqanflm
shift
yield
mqanfi
mqanffi
mqanfli
requir
aatrna
present
peptid
account
product
consist
effici
nativ
gagpol
sequenc
presenc
equimolar
amount
leutrnanaaleu
ribosom
figur
wherea
amount
peptid
small
mettrnamet
omit
increas
wherea
chang
enhanc
expos
hungri
met
codon
site
favor
slippag
absenc
leu
trptrna
effici
increas
expect
unchang
small
amount
product
form
without
addit
leu
trp
mettrna
product
three
altern
frame
found
data
suggest
occur
one
aatrna
lack
howev
aatrna
avail
pathway
preval
understand
kinet
switch
two
differ
regim
monitor
translat
effici
use
codonwalk
approach
absenc
presenc
leutrnanaaleu
rate
constant
calcul
global
fit
time
cours
use
numer
integr
accord
model
shown
figur
addit
inform
estim
rate
constant
arg
gli
incorpor
independ
experi
use
model
mrna
without
frameshift
element
supplementari
figur
c
model
absenc
leutrnanaaleu
introduc
step
result
format
mqanf
product
mqanff
mqanffr
addit
introduc
two
reaction
branch
account
incomplet
convers
ic
product
follow
fraction
initi
complex
enter
translat
introduc
step
account
unproduct
popul
mn
nonreact
also
notic
mqanftrnaph
absenc
asit
ligand
tend
slowli
dissoci
ribosom
supplementari
figur
account
loss
peptidyltrna
introduc
respect
dropoff
reaction
global
fit
time
cours
use
numer
integr
yield
uniqu
solut
rate
constant
figur
b
supplementari
tabl
step
lead
incorpor
second
phe
slow
compar
translat
step
least
time
faster
mqanff
peptid
accumul
convert
peptid
mqanffr
thu
incorpor
second
phe
residu
ratelimit
step
frameshift
commit
ribosom
translat
presenc
leutrnanaaleu
ribosom
synthes
mqanf
peptid
either
continu
translat
leu
incorpor
shift
leutrnanaaleu
bind
leu
incorpor
mqanfl
product
partit
mqanflg
mqanflr
global
fit
time
cours
give
welldefin
rate
constant
step
figur
ratelimit
step
ffr
pathway
rate
constant
similar
isol
ffr
pathway
effici
ffr
pathway
depend
ratio
rate
leutrnanaaleu
bind
rate
slippag
constant
rate
leutrnanaaleu
bind
increas
concentr
explain
addit
excess
leutrnanaaleu
inhibit
ffr
rout
high
concentr
leutrnanaaleu
probabl
bind
leutrnanaaleu
site
higher
slip
frame
condit
ffr
pathway
suppress
flr
pathway
remain
oper
leu
incorpor
effici
flr
rout
defin
transloc
step
partit
take
place
decod
gli
argtrna
figur
ratio
rate
constant
gli
arg
incorpor
respect
supplementari
tabl
give
effici
leu
incorpor
find
leutrnaleu
isoacceptor
read
uua
codon
affect
mechan
effici
prompt
us
valid
key
result
eukaryot
system
first
analyz
rel
abund
human
leutrnaleu
read
uua
codon
trnauaaleu
total
trna
differ
human
cell
type
use
qrtpcr
figur
mainli
infect
tlymphocyt
macrophag
determin
ratio
leutrnauaaleu
leutrnacagleu
read
abund
leu
codon
cug
leutrnauaaleu
less
abund
leutrnacagleu
cell
line
deriv
lymphocyt
hela
cell
wherea
type
human
cell
ratio
figur
leutrnauaaleu
concentr
vari
much
wherea
leutrnacagleu
differ
smaller
except
hela
cell
leutrnacagleu
concentr
increas
supplementari
figur
control
quantifi
rel
abund
valtrnav
isoacceptor
read
rare
gua
codon
abund
gug
codon
trnauacval
isoacceptor
read
rare
codon
time
less
abund
common
trnacacv
except
epitheli
cell
amount
trnauacval
even
lower
figur
rel
abund
trnauaaleu
hela
cell
similar
cell
use
model
hiv
infect
use
total
human
trna
purifi
hela
cell
vitro
translat
experi
describ
first
test
hela
aatrna
perform
translat
combin
eftu
ribosom
e
coli
supplementari
figur
c
conform
human
aatrna
codon
usag
mammalian
mrna
valid
translat
mrna
code
bovin
codon
usag
match
trna
abund
eukaryot
host
e
coli
nativ
human
aatrna
mrna
translat
effici
supplementari
figur
introduc
synonym
mutat
mrna
match
codon
usag
e
coli
reduc
yield
fulllength
product
supplementari
figur
averag
translat
rate
gagpol
nativ
mrna
system
aa
supplementari
figur
translat
gagpol
mrna
fragment
encompass
region
nearest
nativ
elong
aug
codon
gag
mrna
upstream
downstream
second
put
fs
site
downstream
sequenc
predict
form
sl
figur
distinguish
translat
product
introduc
stop
codon
uag
obtain
peptid
amino
acid
aa
length
result
peptid
product
identifi
potenti
product
mutat
nativ
stop
codon
downstream
mrna
denot
nostop
translat
nostop
mrna
leav
product
length
unchang
addit
yield
product
despit
ident
length
product
differ
electrophoret
mobil
due
differ
amino
acid
composit
figur
supplementari
figur
effici
nativ
gagpol
frameshift
sequenc
figur
consist
earlier
invivo
report
format
product
start
delay
may
caus
earli
translat
paus
event
appear
promin
peptid
band
translat
figur
c
supplementari
figur
contrast
product
appear
much
longer
delay
time
synthesi
product
alreadi
complet
ribosom
suggest
may
aris
fraction
ribosom
undergo
long
translat
paus
addit
exogen
leutrnanaaleu
decreas
effici
figur
supplementari
figur
similarli
reduc
fs
effici
observ
uua
codon
mutat
uuc
interrupt
slipperi
run
six
us
chang
ident
trna
read
second
slipperi
codon
abund
trnaph
figur
thu
reassign
second
codon
slipperi
site
abund
trna
effect
ad
excess
trnanaaleu
nativ
sequenc
shorten
slipperi
site
four
u
residu
decreas
fs
disrupt
alon
togeth
diminish
fs
effici
background
level
experi
figur
supplementari
figur
final
test
whether
addit
leutrnauaaleu
alter
frameshift
effici
homolog
reconstitut
mammalian
translat
system
ribosom
subunit
initi
factor
mettrnai
use
form
initi
complex
mrna
unstructur
utr
code
fragment
figur
synthes
mvanflg
mvanflr
peptid
use
trna
hela
cell
aminoacyl
mixtur
requir
amino
acid
without
leu
incorpor
arg
monitor
hplc
analysi
supplementari
figur
control
includ
mrna
code
mvanflr
control
provid
estim
maximum
arg
incorpor
mrna
without
control
effici
fulli
reconstitut
eukaryot
translat
system
presenc
nativ
amount
trnauaaleu
figur
supplementari
figur
leucin
omit
aminoacyl
mixtur
effici
increas
figur
thu
leutrnauaaleu
modul
effici
hiv
mrna
also
homolog
mammalian
translat
system
test
effect
mutat
put
slipperi
sequenc
introduc
mutat
make
either
less
slipperi
figur
supplementari
figur
long
sequenc
unchang
mutat
littl
effect
overal
chang
effici
turn
lead
slight
variat
effici
higher
slipperi
suggest
result
dual
site
rather
alon
replac
rare
cuu
codon
abund
cug
reduc
indic
second
slippag
due
hungri
fs
ustr
disrupt
frameshift
effici
higher
construct
slipperi
compar
nativ
sequenc
presum
secondari
structur
mrna
downstream
supplementari
figur
effect
disrupt
slipperi
site
decreas
frameshift
background
level
thu
support
lowlevel
fs
event
rescu
mutat
also
caus
nativ
sequenc
lead
prematur
termin
translat
show
mrna
oper
two
regim
one
caus
limit
uuaspecif
leutrna
isoacceptor
lead
ffr
product
anoth
ribosom
slip
transloc
slipperi
site
codon
yield
flr
product
switch
two
regim
modul
avail
uuaspecif
trnaleu
show
rare
cell
line
deriv
human
immun
cell
notion
support
vivo
experi
indic
limit
leu
cultur
media
lead
increas
e
coli
exact
effici
gagpol
mrna
differ
depend
type
model
system
phenomenon
note
attribut
differ
translat
rate
vivo
vitro
presum
presenc
bulk
aatrna
also
play
role
compar
figur
uaaspecif
leutrna
modul
effici
e
coli
mammalian
hybrid
translat
system
underscor
notion
frameshift
mechan
univers
conserv
ribosom
also
slip
aatrna
lack
aatrna
suppli
predomin
similarli
translat
e
coli
dnax
mrna
lead
slippag
aatrna
limit
suppli
case
dnax
switch
hungri
frameshift
may
caus
unfavor
condit
eg
amino
acid
starvat
contrast
use
pathway
constitut
due
inher
low
concentr
key
trnauaaleu
isoacceptor
relev
human
cell
fraction
normal
result
function
hiv
product
may
play
role
conjunct
transcript
slippag
revers
transcriptas
ratio
gag
gagpol
product
crucial
viru
propag
must
evolv
achiev
desir
effici
concentr
trnauaaleu
preval
human
cell
uua
codon
rare
human
genom
aend
codon
respect
cognat
trnauaaleu
significantli
underrepres
trna
pool
compar
trnacagleu
read
abund
cug
codon
figur
eukaryot
trna
express
tissuespecif
rel
express
trna
isoacceptor
tissu
show
statist
signific
correl
codon
usag
tissuespecif
gene
low
rel
abund
trnauaaleu
lymphocytederiv
cell
type
may
result
adapt
codon
usag
cell
hand
rare
uua
codon
account
leu
codon
lateexpress
gene
includ
gag
pol
express
late
hiv
gene
would
increas
demand
trnauaaleu
rare
respect
cell
may
delay
decod
uua
codon
includ
key
codon
slipperi
sequenc
deliveri
uua
codon
slipperi
site
slow
ribosom
switch
ffr
rout
lead
robust
codon
usag
dispar
hiv
human
host
util
disrupt
late
stage
viru
product
exampl
interferoninduc
antivir
protein
schlafen
select
abrog
express
late
viral
protein
codonusagedepend
manner
induc
specif
cleavag
trna
long
variabl
loop
includ
serin
leucin
trna
alreadi
rare
trna
trnauaaleu
reduc
trna
avail
might
manifest
ratelimit
step
synthesi
protein
involv
trna
trnadepend
modul
frameshift
also
report
within
expand
cag
stretch
huntingtin
gene
translat
expand
cag
repeat
mutant
huntingtin
exon
lead
deplet
charg
glntrnacuggln
pair
cag
codon
result
translat
frameshift
frameshift
frequenc
vari
strongli
among
differ
cell
line
higher
cell
intrins
lower
concentr
trnacuggln
emphas
biolog
signific
trna
concentr
modul
frameshift
effici
antihiv
therapi
proteas
inhibitor
lead
accumul
mutat
proteas
impair
recognit
specif
cleavag
site
allow
polyprotein
matur
mutat
proteas
secondari
mutat
aris
harbor
cleavag
site
gag
polyprotein
mutat
substitut
leu
phe
enhanc
van
der
waal
interact
substrat
mutant
proteas
therebi
increas
proteas
activ
mutat
produc
slipperi
sequenc
support
role
depend
sequenc
nativ
joint
activ
differ
alon
mutat
nonshifti
sequenc
mutat
suffici
support
level
may
suffici
viru
propag
find
allevi
detriment
effect
mutat
consist
previou
vitro
vivo
report
interestingli
antivir
therapi
drugresist
herp
simplex
virus
also
develop
unusu
slipperi
site
support
level
suffici
viru
replic
pathogen
despit
treatment
similarli
mutat
gagpol
mrna
modul
fs
effici
also
improv
activ
mutant
proteas
emerg
upon
proteas
inhibitor
treatment
evolutionari
pressur
led
conserv
known
sequenc
seem
allow
rapid
adapt
antivir
therapi
thu
constitut
use
differ
fs
regim
evolv
ensur
low
crucial
level
fs
requir
prolifer
